| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 09/20/2001 | WO2001068068A2 Compounds capable of binding with the cytoskeleton |
| 09/20/2001 | WO2001068067A2 Use of deramciclane for the treatment of anxiety and depression |
| 09/20/2001 | WO2001068065A2 Compositions comprising blockers of l-dopa renal cell transfer for the treatment of parkinson's disease |
| 09/20/2001 | WO2001068063A2 Novel use of (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts |
| 09/20/2001 | WO2001068033A2 Il-8 receptor antagonists |
| 09/20/2001 | WO2001029070A8 Modulation of t cell differentiation for the treatment of t helper cell mediated diseases |
| 09/20/2001 | WO2001027118A3 Bicyclic imidazo-5-yl-amine derivatives |
| 09/20/2001 | WO2001027110A3 Bicyclic imidazo-3-yl-amine derivatives which are substituted on the sixth ring |
| 09/20/2001 | WO2001027109A3 Tert.-butyl-(7-methyl-imidazo[1,2-a]pyridine-3-yl)-amine derivatives |
| 09/20/2001 | WO2001019851A3 Opaminergic neuronal survival-promoting factors and uses thereof |
| 09/20/2001 | WO2001019850A3 Nrage nucleic acids and polypeptides and uses thereof |
| 09/20/2001 | WO2001019819A3 Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment |
| 09/20/2001 | WO2001018051A3 Mammalian interleukin-12 p40 and interleukin b30, combinations thereof, antibodies, uses in pharmaceutical compositions |
| 09/20/2001 | WO2001016603A3 Analysis and treatment of body weight and eating disorders |
| 09/20/2001 | WO2001015664A3 Coformulation methods and their products |
| 09/20/2001 | WO2001014424A3 Human ctla-4 antibodies and their uses |
| 09/20/2001 | WO2000047583A9 Cyclic substituted fused pyrrolocarbazoles and isoindolones |
| 09/20/2001 | WO2000046246A8 Alpha-2-macroglobulin therapies and drug screening methods for alzheimer's disease |
| 09/20/2001 | WO2000027378A3 Cystine derivatives as therapeutic agents for matrix metalloprotease related diseases |
| 09/20/2001 | WO2000009537A3 Compounds having growth hormone releasing activity |
| 09/20/2001 | US20010023260 Method for preventing and treating peripheral neuropathy by administering selegiline |
| 09/20/2001 | US20010023257 Hypotensive agents; anticholesterol agents |
| 09/20/2001 | US20010023256 Reducing concentration of oxygen metabolites |
| 09/20/2001 | US20010023253 Novel compound |
| 09/20/2001 | US20010022964 Fast dissolving orally consumable films |
| 09/20/2001 | EP1143960A3 Cystine derivatives as therapeutic agents for matrix metalloprotease related diseases |
| 09/20/2001 | CA2411732A1 Crystalline base of citalopram |
| 09/20/2001 | CA2403679A1 Il-8 receptor antagonists |
| 09/20/2001 | CA2403442A1 Use of nateglinide alone or in combination for the treatment or prevention of diabetic complications |
| 09/20/2001 | CA2403420A1 Compounds capable of binding with the cytoskeleton |
| 09/20/2001 | CA2403393A1 Methods and compositions for immunoregulation |
| 09/20/2001 | CA2403350A1 Use of deramciclane for the treatment of anxiety and depression |
| 09/20/2001 | CA2403252A1 Neutral antagonists and use thereof in treating drug abuse |
| 09/20/2001 | CA2403220A1 Methods and compositions for the regulation of vasoconstriction |
| 09/20/2001 | CA2403149A1 2-phenylpyran-4-one derivatives |
| 09/20/2001 | CA2403062A1 Il-8 receptor antagonists |
| 09/20/2001 | CA2403017A1 5-amide substituted diarylamines as mex inhibitors |
| 09/20/2001 | CA2403000A1 Embryonic stem cells and neural progenitor cells derived therefrom |
| 09/20/2001 | CA2402898A1 Novel lipoic acid heterocyclic or benzene derivatives, preparation and use thereof as medicines |
| 09/20/2001 | CA2402891A1 Il-8 receptor antagonists |
| 09/20/2001 | CA2402869A1 Method for the preparation of 5-cyano-1-(4-fluorophenyl)-1,3-dihydroisobenzofurans |
| 09/20/2001 | CA2402865A1 Opioid formulations |
| 09/20/2001 | CA2402733A1 Effects of glucagon-like peptide-1 (7-36) on antro-pyloro-duodenal motility |
| 09/20/2001 | CA2402614A1 Insulin homolog polypeptide zins4 |
| 09/20/2001 | CA2402557A1 Method for the preparation of citalopram |
| 09/20/2001 | CA2402553A1 Stepwise alkylation of 5-substituted 1-(4-fluorophenyl)-1,3-dihydroisobenzofurans |
| 09/20/2001 | CA2402549A1 Substituted beta-carbolines |
| 09/20/2001 | CA2402427A1 Dihydroimidazo[2,1-b]thiazole and dihydro-5h-thiazolo[3,2-a]pyrimidines as antidepressant agents |
| 09/20/2001 | CA2402402A1 Use of (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane for treating adverse effects of anti-parkinsonian drugs |
| 09/20/2001 | CA2402388A1 Method for the preparation of citalopram |
| 09/20/2001 | CA2402386A1 Method for the preparation of citalopram |
| 09/20/2001 | CA2402296A1 Intradermal-penetration agents for topical local anesthetic administration |
| 09/20/2001 | CA2402248A1 Polypeptides and nucleic acids encoding same |
| 09/20/2001 | CA2400238A1 Human nim1 kinase |
| 09/20/2001 | CA2400106A1 Antibodies to human cd154 |
| 09/20/2001 | CA2373411A1 5-substituted arylpyrimidines |
| 09/20/2001 | CA2373110A1 Production of chimeric capsid vectors |
| 09/19/2001 | EP1134290A2 Pharmacophore models for the identification of the CYP2D6 inhibitory potency of selective serotonin reuptake inhibitors |
| 09/19/2001 | EP1134230A1 Novel polypeptide |
| 09/19/2001 | EP1134215A1 2-oxo-imidazolidine-4-carboxylic acid hydroxamine compounds that inhibit matrix metalloproteinases |
| 09/19/2001 | EP1133997A2 Treatment of immune diseases with beta-interferon |
| 09/19/2001 | EP1133986A1 Use of deramciclane for the treatment of anxiety and depression |
| 09/19/2001 | EP1133699A1 Prevention and treatment of amyloid-associated disorders |
| 09/19/2001 | EP1133557A2 Growth factor modulators |
| 09/19/2001 | EP1133494A1 8-azabicyclo 3.2.1]oct-2-ene and -octane derivatives |
| 09/19/2001 | EP1133492A1 Process for the preparation of paroxetine hydrochloride |
| 09/19/2001 | EP1133487A1 Scavenger compounds |
| 09/19/2001 | EP1133486A2 Nonsteroidal antiinflammatories |
| 09/19/2001 | EP1133484A2 Heterocyclic derivatives and their use as integrin inhibitors |
| 09/19/2001 | EP1133477A1 Substituted benzimidazoles and their use as parp inhibitors |
| 09/19/2001 | EP1133475A1 Substituted benzo de]isoquinoline-1,3-diones |
| 09/19/2001 | EP1133474A1 3-substituted-4-arylquinolin-2-one derivatives as potassium channel modulators |
| 09/19/2001 | EP1133467A1 Ion channel modulating agents |
| 09/19/2001 | EP1133459A1 Sertraline hydrochloride polymorphs |
| 09/19/2001 | EP1133300A1 Desmethylolanzapine compositions and methods |
| 09/19/2001 | EP1133299A1 2-hydroxymethylolanzapine compositions and methods |
| 09/19/2001 | EP1133297A1 Novel therapeutic use of 1,6-dimethyl-8beta-hydroxymethyl-10alpha-methoxyergoline |
| 09/19/2001 | EP1133296A1 Novel therapeutic application of nicergoline |
| 09/19/2001 | EP1133295A1 Use of nicergoline for treating spasmodism |
| 09/19/2001 | EP1133294A1 Compositions and methods for the treatment of alzheimer's disease, central nervous system injury, and inflammatory diseases |
| 09/19/2001 | EP1133293A1 Use of n-substituted azabicycloalkane derivatives for treating diseases of the central nervous system |
| 09/19/2001 | EP1133292A1 A new pharmaceutical composition |
| 09/19/2001 | EP1133290A1 Use of effectors of the central cholinergic nervous system |
| 09/19/2001 | EP1133284A1 New process |
| 09/19/2001 | EP1133280A1 Method of preparing stable suspensions of insoluble microparticles |
| 09/19/2001 | EP1133230A1 Dosage formulations for acetylcholinesterase inhibitors |
| 09/19/2001 | EP1015416B1 Method for the preparation of citalopram |
| 09/19/2001 | EP0880522B1 5H,10H-IMIDAZO[1,2-a]INDENO[1,2-e]PYRAZINE-4-ONE DERIVATIVES AMPA AND NMDA RECEPTORS ANTAGONISTS, PREPARATION THEREOF, INTERMEDIATES THEREOF AND DRUGS CONTAINING SAME |
| 09/19/2001 | EP0874849B1 2,7-substituted octahydro-pyrrolo 1,2-a]pyrazine derivatives |
| 09/19/2001 | EP0871420B1 Triacetin as a transdermal penetration enhancer |
| 09/19/2001 | EP0869954B1 Heterocyclic compounds for use in the treatment of neurogenic inflammation |
| 09/19/2001 | EP0869952B1 5-naphthalen-1-yl-1,3-dioxane derivatives, preparation and therapeutical use thereof |
| 09/19/2001 | EP0853616B1 Bicyclic 4-aralkylaminopyrimidine derivatives as tyrosine kinase inhibitors |
| 09/19/2001 | EP0839144B1 Piperazine derivatives as therapeutic agents |
| 09/19/2001 | EP0820443B1 Heterocyclic compounds for treating diabetes |
| 09/19/2001 | EP0770077B1 Process for the preparation of 2-(1-azabicyclo(2.2.2)oct-3-yl) -2,4,5,6-tetrahydro-1h-benz(de)isoquinolin-1-one and intermediate product |
| 09/19/2001 | EP0640099B1 Peptides having tachykinin antagonist activity |
| 09/19/2001 | EP0500864B1 Antimuscarinic bronchodilators |
| 09/19/2001 | CN1313855A Inhibitors of alpha4Betal mediated cell adhesion alpha Beta |
| 09/19/2001 | CN1313846A C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cystenine proteases |